Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02193971 |
|
Recruitment Status :
Recruiting
First Posted : July 18, 2014
Last Update Posted : March 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
-
Study objectives
- To compare the safety and long-term efficacy of coronary stenting with biostable polymer drug-eluting stent (Promus PremierTM, Xience Alpine®, Resolute Onyx®) with biodegradable polymer drug-eluting stent (Biomatrix®, Biomatrix Flex®, Nobori®, Ultimaster®, Synergy ® and Orsiro®) in patients with acute coronary syndrome
- To compare the efficacy and safety of 5 mg prasugrel maintenance therapy compared with 10 mg prasugrel maintenance therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention
- Study design :
Prospective, open-label, 2-by-2 multifactorial, randomized, multicenter trial to test the following in CHD patients
- Non-inferiority of biostable polymer drug-eluting stent (Promus PremierTM, Xience Alpine®, Resolute Onyx®) compared with biodegradable polymer drug-eluting stent (Biomatrix®, Biomatrix Flex®, Nobori®, Ultimaster®, Synergy ® and Orsiro®) in terms of patient-oriented composite outcome
- Non-inferiority of 5 mg compared to 10 mg dose of prasugrel maintenance in terms of major adverse cardiovascular events
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Coronary Syndrome | Device: BS-DES (Biostable polymer drug-eluting stent) Device: BD-DES (Biodegradable polymer drug-eluting stent) Drug: Prasugrel 5mg | Phase 4 |
About 3400 patients derived from a population of Korean patients with acute coronary syndrome receiving percutaneous coronary intervention will be enrolled in the present trial.
All patients will receive a loading dose of aspirin (300 mg) and prasugrel (60 mg bolus) will be administered. Sixty-mg-loading dose of prasugrel will be given regardless of pretreated antiplatelet agents (clopidogrel, ticagrelor, or cilostazol). However, in patients who already loaded with other antiplatelet agents (clopidigrel, ticagrelor, or cilostazol), reduced dose (30mg) or omission of prasugrel loading is acceptable. Following angiography, patients with significant diameter stenosis >50% of coronary artery or graft vessel by visual estimation that have documented myocardial ischemia or symptoms of angina, and have lesions that are eligible for coronary intervention without any exclusion criteria, will be randomized 1:1 to either receive either BS-DES or BD-DES group.
At 1-month clinical follow-up, patients eligible for antiplatelet comparison will be additionally randomized 1:1 to either receive the reduce dose of prasugrel (5 mg daily) or conventional dose (10 mg daily). The exclusion criteria (age ≥75 years, body weight <60 kg, or history of TIA or stroke) is classified as observational cohort. Post-PCI, dual antiplatelet therapy is recommended for at least 1 year. Follow-up data will be collected until 3-year after index procedure.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 3384 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES (Promus PremierTM, Xience Alpine®, and Resolute Onyx®) With Biodegradable Polymer DES (Biomatrix®, Biomatrix Flex®, Nobori®, Ultimaster®,Synergy®, and Orsiro®)and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention |
| Study Start Date : | July 2014 |
| Estimated Primary Completion Date : | October 2018 |
| Estimated Study Completion Date : | June 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: BS-DES with prasugrel 10mg daily
BS-DES with prasugrel 10mg daily
|
Device: BS-DES (Biostable polymer drug-eluting stent)
Other Names:
|
|
Active Comparator: BS-DES with prasugrel 5mg daily
BS-DES with prasugrel 5mg daily
|
Device: BS-DES (Biostable polymer drug-eluting stent)
Other Names:
Drug: Prasugrel 5mg Use prasugrel 5mg daily for maintaning dose
Other Name: Prasugrel |
|
Experimental: BD-DES with prasugrel 10mg daily
BD-DES with prasugrel 10mg daily
|
Device: BD-DES (Biodegradable polymer drug-eluting stent)
Other Names:
|
|
Experimental: BD-DES with prasugrel 5mg daily
BD-DES with prasugrel 5mg daily
|
Device: BD-DES (Biodegradable polymer drug-eluting stent)
Other Names:
Drug: Prasugrel 5mg Use prasugrel 5mg daily for maintaning dose
Other Name: Prasugrel |
- Stent arm : patient-oriented composite outcome (POCO), defined as a composite of all death, myocardial infarction (MI) or repeat revascularization [ Time Frame: 12months ]
- Antiplatelet arm : major adverse cardiovascular event (MACE), defined as a composite of all death, MI, stent thrombosis, repeat revascularization, CVA, and BARC class ≥2 bleeding [ Time Frame: 12months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject must be ≥ 18 years
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
- Subject must have a culprit lesion in a native coronary artery with significant stenosis (>50% by visual estimate) eligible for stent implantation
- Subject must have clinical diagnosis of acute coronary syndrome
Exclusion Criteria:
- Following patients will be enrolled in stent comparison, but excluded from antiplatelet comparison. They will be classified as observational cohort.
- Subjects ≥75 years
- Body weight <60 kg
- History of TIA or stroke
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Biolimus, Everolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)
- Patients with active pathologic bleeding
- Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
- Systemic (intravenous) Biolimus, or everolimus use within 12 months.
- Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
- History of bleeding diathesis, known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02193971
| Contact: Kyung-Woo Park, MD, PhD | 82-2-2072-0244 | kwparkmd@snu.ac.kr |
| Korea, Republic of | |
| Seoul National University Hospital | Recruiting |
| Seoul, Korea, Republic of, 110-744 | |
| Contact: Kyung Woo Park, MD, PhD 82-2-2072-0244 kwparkmd@snu.ac.kr | |
| Contact: Hyo-Soo Kim, MD, PhD 82-2-2072-2226 hyosoo@snu.ac.kr | |
| Study Chair: | Hyo-Soo Kim, MD, PhD | Seoul National University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Seoul National University Hospital |
| ClinicalTrials.gov Identifier: | NCT02193971 History of Changes |
| Other Study ID Numbers: |
HOST REDUCE POLYTECH RCT |
| First Posted: | July 18, 2014 Key Record Dates |
| Last Update Posted: | March 9, 2018 |
| Last Verified: | October 2017 |
Keywords provided by Seoul National University Hospital:
|
Acute coronary syndrome Drug eluting stent Everolimus Prasugrel |
Additional relevant MeSH terms:
|
Syndrome Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Disease Pathologic Processes |
Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Prasugrel Hydrochloride Platelet Aggregation Inhibitors |